Literature DB >> 18322182

Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes.

Kristian Hallermalm1, Kazutake Seki, Anna De Geer, Bruce Motyka, R Chris Bleackley, Martine J Jager, Christopher J Froelich, Rolf Kiessling, Victor Levitsky, Jelena Levitskaya.   

Abstract

IFN-gamma, a pleiotropic immune regulator, is implicated in both tumor immune surveillance and selection of tumor variants resistant to immune control, i.e., immunoediting. In uveal melanoma patients, elevated serum levels of IFN-gamma correlate with the spread of metastasis and represent a negative prognostic marker. Treatment with IFN-gamma boosted the MHC class I presentation machinery in uveal melanoma cells but suppressed their MHC class I-restricted CTL lysis. Tumor cells exposed to IFN-gamma efficiently activated specific CTL but were less susceptible to permeabilization by perforin and exhibited a decreased capacity to bind and incorporate granzyme B. These results define a novel mechanism of resistance to granule-mediated CTL lysis in human tumors. Furthermore, the data suggest that immunoediting is not limited to genetic or epigenetic changes resulting in stable cellular phenotypes but also involves an inducible modulation of tumor cells in response to a microenvironment associated with immune activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322182     DOI: 10.4049/jimmunol.180.6.3766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.

Authors:  Rodolfo D Vicetti Miguel; Thomas L Cherpes; Leah J Watson; Kyle C McKenna
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

2.  In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.

Authors:  Joëlle Riond; Stéphane Rodriguez; Marie-Laure Nicolau; Talal al Saati; Jean Edouard Gairin
Journal:  Cancer Immun       Date:  2009-11-02

Review 3.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 4.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 5.  Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State.

Authors:  Masoud H Manjili
Journal:  Cancer Res       Date:  2017-05-15       Impact factor: 12.701

Review 6.  Biology of advanced uveal melanoma and next steps for clinical therapeutics.

Authors:  Jason J Luke; Pierre L Triozzi; Kyle C McKenna; Erwin G Van Meir; Jeffrey E Gershenwald; Boris C Bastian; J Silvio Gutkind; Anne M Bowcock; Howard Z Streicher; Poulam M Patel; Takami Sato; Jeffery A Sossman; Mario Sznol; Jack Welch; Magdalena Thurin; Sara Selig; Keith T Flaherty; Richard D Carvajal
Journal:  Pigment Cell Melanoma Res       Date:  2014-09-01       Impact factor: 4.693

Review 7.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

8.  Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.

Authors:  Lata Singh; Mithalesh Kumar Singh; Maria Cristina Kenney; Martine J Jager; Moshahid Alam Rizvi; Rachna Meel; Neiwete Lomi; Sameer Bakhshi; Seema Sen; Seema Kashyap
Journal:  Cancer Immunol Immunother       Date:  2020-11-02       Impact factor: 6.968

9.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

Review 10.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.